Ding Yan, Zhang Yong, Wen Cheng, Xie Hua-Ping, Xie Bing-Lin, Li Lihua, Wu Weijing, Xie Ding-Hua, Lai Ruosha
Department of Otorhinolaryngology-Head & Neck Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Laboratory of Animal Nutrition and Human Health, Hunan International Joint Laboratory of Animal Intestinal Ecology and Health, College of Life Science, Hunan Normal University, Changsha, Hunan, China.
Eur Arch Otorhinolaryngol. 2025 Apr 7. doi: 10.1007/s00405-025-09378-w.
To analyze SLC26A4 gene mutations in children with large vestibular aqueduct syndrome (LVAS) with or without Mondini malformation, and to compare their hearing phenotypes, rehabilitation outcomes, and learning performance after cochlear implantation.
We used T7 Endonuclease I enzyme digestion to detect SLC26A4 mutations in 48 children with LVAS without Mondini malformation (EVA group), 29 children with LVAS and Mondini malformation (EVA + MD group). Negative results were confirmed by Sanger sequencing. Auditory performance (CAP) and speech intelligibility (SIR) scores assessed hearing and speech rehabilitation outcomes, while academic performance evaluated learning post-cochlear implantation.
Electrophoresis showed that the positive detection rates of SLC26A4 mutations were 89.58% in the EVA group, 89.66% in the EVA + MD group, and 0% in the control group. In the EVA group, the most common mutations were in exons 7 + 8 (52.08%), 11 + 12 (22.92%), and 19 (18.75%). In the EVA + MD group, the predominant mutations were in exons 11 + 12 (51.72%), 4 (34.48%), 7 + 8 (27.59%), and 19 (24.14%). The EVA + MD group had higher detection rates for two-site (37.93%) and three-site compound heterozygous mutations (13.79%) compared to the EVA group (22.92% and 10.42%, respectively). The median diagnosis time for profound hearing loss was 6.62 months in the EVA + MD group versus 10.56 months in the EVA group. There were no significant differences in CAP and SIR scores between the groups, but the EVA group showed better learning performance.
This study reports, for the first time, multiple cases exhibiting a three-site compound heterozygous mutation in the SLC26A4 gene. The hotspot exons of the SLC26A4 gene differ between children with simple LVAS and those with LVAS accompanied by Mondini malformation. Children with both conditions show earlier onset of profound hearing loss and poorer learning performance compared to those with only LVAS.
分析伴或不伴Mondini畸形的大前庭导水管综合征(LVAS)患儿的SLC26A4基因突变情况,并比较其听觉表型、康复效果以及人工耳蜗植入后的学习表现。
我们采用T7核酸内切酶I酶切法检测48例不伴Mondini畸形的LVAS患儿(EVA组)、29例伴Mondini畸形的LVAS患儿(EVA+MD组)的SLC26A4基因突变情况。阴性结果通过桑格测序进行确认。听觉表现(CAP)和言语清晰度(SIR)评分评估听力和言语康复效果,而学业表现则评估人工耳蜗植入后的学习情况。
电泳显示,EVA组SLC26A4基因突变的阳性检出率为89.58%,EVA+MD组为89.66%,对照组为0%。在EVA组,最常见的突变位于外显子7+8(52.08%)、11+12(22.92%)和19(18.75%)。在EVA+MD组,主要突变位于外显子11+12(51.72%)、4(34.48%)、7+8(27.59%)和19(24.14%)。与EVA组相比,EVA+MD组的双位点(3(7.93%)和三位点复合杂合突变(13.79%)的检出率更高(EVA组分别为22.92%和10.42%)。EVA+MD组重度听力损失的中位诊断时间为6.62个月,而EVA组为10.56个月。两组之间的CAP和SIR评分无显著差异,但EVA组的学习表现更好。
本研究首次报道了多例SLC26A4基因出现三位点复合杂合突变的病例。单纯LVAS患儿与伴Mondini畸形的LVAS患儿的SLC26A4基因热点外显子不同。与仅患有LVAS的患儿相比,同时患有这两种疾病的患儿重度听力损失发病更早,学习表现更差。